Novavax slashes revenue forecasts amid slow demand for COVID-19 vaccine
BioPharma
Source: biopharmadive.com
Stay updated with breaking news from Stan Erck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Here's why we like Novavax, Orthopediatrics, and Pliant Therapeutics.
What does the future hold for this COVID-19 vaccination stock?
COVID is not over, but the situation for the many vaccine developers late to the party (including Novavax) is unclear. See if NVAX stock is a buy or sell.
Novavax, Inc. (NASDAQ:NASDAQ:NVAX) Q1 2022 Results Earnings Conference Call May 09, 2022, 04:30 PM ET Company Participants Silvia Taylor - SVP, Global Corporate Affairs & IR Stan Erck -...